当前位置: 首页 >> 检索结果
2703. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
作者: Martin Dreyling.;Jeanette Doorduijn.;Eva Giné.;Mats Jerkeman.;Jan Walewski.;Martin Hutchings.;Ulrich Mey.;Jon Riise.;Marek Trneny.;Vibeke Vergote.;Ofer Shpilberg.;Maria Gomes da Silva.;Sirpa Leppä.;Linmiao Jiang.;Stephan Stilgenbauer.;Andrea Kerkhoff.;Ron D Jachimowicz.;Melania Celli.;Georg Hess.;Luca Arcaini.;Carlo Visco.;Tom van Meerten.;Stefan Wirths.;Pier Luigi Zinzani.;Urban Novak.;Peter Herhaus.;Fabio Benedetti.;Kristina Sonnevi.;Christine Hanoun.;Matthias Hänel.;Judith Dierlamm.;Christiane Pott.;Wolfram Klapper.;Döndü Gözel.;Christian Schmidt.;Michael Unterhalt.;Marco Ladetto.;Eva Hoster.
来源: Lancet. 2024年403卷10441期2293-2306页
Adding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed to investigate whether the addition of ibrutinib results in a superior clinical outcome compared with the pre-trial immunochemotherapy standard with ASCT or an ibrutinib-containing treatment without ASCT. We also investigated whether standard treatment with ASCT is superior to a treatment adding ibrutinib but without ASCT.
2704. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.
作者: Andrew J Shattock.;Helen C Johnson.;So Yoon Sim.;Austin Carter.;Philipp Lambach.;Raymond C W Hutubessy.;Kimberly M Thompson.;Kamran Badizadegan.;Brian Lambert.;Matthew J Ferrari.;Mark Jit.;Han Fu.;Sheetal P Silal.;Rachel A Hounsell.;Richard G White.;Jonathan F Mosser.;Katy A M Gaythorpe.;Caroline L Trotter.;Ann Lindstrand.;Katherine L O'Brien.;Naor Bar-Zeev.
来源: Lancet. 2024年403卷10441期2307-2316页
WHO, as requested by its member states, launched the Expanded Programme on Immunization (EPI) in 1974 to make life-saving vaccines available to all globally. To mark the 50-year anniversary of EPI, we sought to quantify the public health impact of vaccination globally since the programme's inception.
2709. Extended optical treatment versus early patching with an intensive patching regimen in children with amblyopia in Europe (EuPatch): a multicentre, randomised controlled trial.
作者: Frank A Proudlock.;Michael Hisaund.;Gail Maconachie.;Eleni Papageorgiou.;Ali Manouchehrinia.;Annegret Dahlmann-Noor.;Payal Khandelwal.;Jay Self.;Christina Beisse.;Irene Gottlob.; .
来源: Lancet. 2024年403卷10438期1766-1778页
Amblyopia, the most common visual impairment of childhood, is a public health concern. An extended period of optical treatment before patching is recommended by the clinical guidelines of several countries. The aim of this study was to compare an intensive patching regimen, with and without extended optical treatment (EOT), in a randomised controlled trial.
|